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Abstract
While the addition of cetuximab to radiotherapy improves clinical outcomes in locoregionally
advanced head and neck squamous cell cancers, there are a small number of reports of severe
radiation dermatitis occurring with this therapeutic combination. We present the case of a 69 year
old male who developed severe radiation dermatitis following treatment with cetuximab and
radiotherapy for a locoregionally advanced head and neck squamous cell cancer.
Introduction
The addition of cetuximab to radiotherapy improves local
control and overall survival in locoregionally advanced
head and neck squamous cell cancer. However, evidence
is emerging that severe radiation dermatitis can occur in
patients receiving cetuximab. We present the case of a 69
year old male who developed severe radiation dermatitis
following treatment with cetuximab and radiotherapy for
a locoregionally advanced head and neck squamous cell
cancer.
Case presentation
A 69-year-old Caucasian male developed a severe rash two
weeks after starting treatment with concurrent cetuximab
and radiotherapy for a loco-regionally advanced right
buccal head and neck squamous cell cancer (HNSCC).
Two months earlier, magnetic resonance imaging (MRI)
identified a 3.8 × 1.4 × 3.6 cm right buccal mass with a 1.7
cm left sided midcervical lymph node. There was no other
disease on fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET). His disease was considered unresecta-
ble and cisplatin was contra-indicated because of sensori-
neural industrial hearing impairment. He commenced
radiotherapy (66 Grays in 33 fractions) and cetuximab
(250 mg/m2 weekly during radiation, with a single dose of
400 mg/m2 the week prior to radiation).
He had undergone resection of a lymph node-negative
HNSCC of the left floor of mouth five years previously. In
addition, a right retromolar trigone HNSCC had been
resected 10 years previously. No post-operative radiother-
apy was administered in either case. The only other his-
tory was hypertension treated with metoprolol. He had
smoked 1 pack a day for 30 years, having ceased 30 years
prior. He drank minimal alcohol. He lived with his wife
and was a retired builder. There was no relevant family
history.
Two weeks after commencing treatment he developed a
severe painful skin reaction within the radiotherapy field.
This progressively worsened, necessitating hospitalisation
one week after completing radiotherapy. On examination,
he had a moist, desquamating, circumferential, erythema-
tous rash on the lower half of his face and upper neck. He
was dehydrated and febrile at 38.5°C. He had oral
mucositis but no candidiasis. There was a mild acneiform
rash over the upper torso and arms. Other vital signs and
the remaining physical examination were unremarkable.
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Swabs were taken from the desquamating rash and
cytomegalovirus DNA was detected on polymerase chain
reaction. He was given a three-month course of valganci-
clovir (900 mg twice daily for three weeks, followed by
900 mg daily). The rash was treated with twice daily dress-
ings and silver sulphadiazine cream and he was dis-
charged home after three weeks. FDG-PET performed
three months later showed complete metabolic remis-
sion.
Cetuximab is a chimeric monoclonal antibody against
epidermal growth factor receptor (EGFR), a receptor tyro-
sine kinase that is up-regulated in more than 90% of
HNSCCs[1]. In a pivotal phase III study of 424 patients
with locoregionally advanced HNSCCs[2], the addition of
cetuximab to radiotherapy significantly improved locore-
gional control (50% versus 41%), three-year survival
(55% vs. 45%) and median survival (49 months versus 29
months). The only grade 3 toxicities more common in the
cetuximab group were infusional reactions and acneiform
rash (17% versus 1%).
Interestingly, there was no significant increase in grade 3
radiation dermatitis for the cetuximab group (23% versus
18%) in this study. However, multiple reports have subse-
quently emerged of severe radiation dermatitis complicat-
ing treatment with concurrent cetuximab and
radiotherapy for HNSCCs [3-5]. Radiation dermatitis
must be distinguished from the acneiform rash of the face,
neck and upper torso that affects up to 2/3 of patients
receiving anti-EGFR agents[6,7].
It should also be noted that most patients receiving radio-
therapy alone for HNSCCs experience some degree of
radiation dermatitis[8]. Nonetheless, consensus guide-
lines have now been developed for the prevention and
management of cutaneous toxicity in patients with
HNSCCs treated with cetuximab and radiotherapy[8].
These guidelines emphasise the need for adequate
hygiene and hydration of the skin. More severe reactions
may require dressings, topical anti-inflammatory agents
and antimicrobials for secondary infections.
Conclusion
The case presented here, in addition to others in the recent
literature, highlights the risk of severe radiation dermatitis
in patients with HNSCCs treated with cetuximab and radi-
otherapy. Clinicians must be aware of this risk, and imple-
ment appropriate strategies for prevention and treatment
of radiation dermatitis in these patients.
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